BR0309624A - Uso de xenÈnio para o controle de deficiências neurológicas associadas com desvio cardiopulmonar - Google Patents

Uso de xenÈnio para o controle de deficiências neurológicas associadas com desvio cardiopulmonar

Info

Publication number
BR0309624A
BR0309624A BR0309624-6A BR0309624A BR0309624A BR 0309624 A BR0309624 A BR 0309624A BR 0309624 A BR0309624 A BR 0309624A BR 0309624 A BR0309624 A BR 0309624A
Authority
BR
Brazil
Prior art keywords
xenium
cardiopulmonary bypass
disabilities associated
neurological disabilities
control neurological
Prior art date
Application number
BR0309624-6A
Other languages
English (en)
Inventor
Nicholas Peter Franks
Mervyn Maze
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0309624(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Publication of BR0309624A publication Critical patent/BR0309624A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Credit Cards Or The Like (AREA)

Abstract

"USO DE XENÈNIO PARA O CONTROLE DE DEFICIêNCIAS NEUROLóGICAS ASSOCIADAS COM DESVIO CARDIOPULMONAR". A presente invenção refere-se a métodos de controle de deficiências neurológicas em pacientes que tenham sido submetidos a desvio cardiopulmonar (CPB) pela administração de xenónio ao referido paciente.
BR0309624-6A 2002-05-01 2003-05-01 Uso de xenÈnio para o controle de deficiências neurológicas associadas com desvio cardiopulmonar BR0309624A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0209998.4A GB0209998D0 (en) 2002-05-01 2002-05-01 Use
PCT/GB2003/001867 WO2003092707A1 (en) 2002-05-01 2003-05-01 Use of xenon for the control of neurological deficits associated with cardiopulmonary bypass

Publications (1)

Publication Number Publication Date
BR0309624A true BR0309624A (pt) 2005-02-09

Family

ID=9935900

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309624-6A BR0309624A (pt) 2002-05-01 2003-05-01 Uso de xenÈnio para o controle de deficiências neurológicas associadas com desvio cardiopulmonar

Country Status (12)

Country Link
US (1) US7442383B2 (pt)
EP (1) EP1499329B2 (pt)
JP (2) JP4939751B2 (pt)
AT (1) ATE427750T1 (pt)
AU (1) AU2003227896B2 (pt)
BR (1) BR0309624A (pt)
CA (1) CA2483097C (pt)
DE (1) DE60327068D1 (pt)
ES (1) ES2323582T5 (pt)
GB (1) GB0209998D0 (pt)
MX (1) MXPA04010855A (pt)
WO (1) WO2003092707A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
JP2007509091A (ja) * 2003-10-21 2007-04-12 エイジーエイ、アクティエボラーグ プログラム細胞死の防止のためのキセノンの使用
GB0418540D0 (en) 2004-08-19 2004-09-22 Protexeon Ltd Use
EP1980260A1 (en) 2007-04-10 2008-10-15 Nicholas Peter Franks Use of hyperbaric conditions to provide neuroprotection
EP1980261A1 (en) 2007-04-10 2008-10-15 Nicholas Peter Franks Use of helium with oxygen to provide neuroprotection
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
AU2014233018A1 (en) 2013-03-15 2015-10-01 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
FR3021220B1 (fr) * 2014-05-21 2017-08-25 Air Liquide Association de xenon et d’un antioxydant pour lutter contre une maladie neurodegenerative de type maladie de parkinson
US11229712B2 (en) * 2016-06-03 2022-01-25 Lakehead University In vivo detection of a xenon-binding cage molecule
CN113646021A (zh) * 2019-03-25 2021-11-12 马林克罗特制药爱尔兰有限公司 气体递送系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US6589621B1 (en) * 1998-07-01 2003-07-08 Dow Global Technologies Inc. Thermally stable polyetheramines
DE19910986C2 (de) * 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
DE19933704A1 (de) * 1999-07-19 2001-01-25 Michael Georgieff Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use

Also Published As

Publication number Publication date
EP1499329A1 (en) 2005-01-26
EP1499329B2 (en) 2012-05-23
JP2011102290A (ja) 2011-05-26
GB0209998D0 (en) 2002-06-12
WO2003092707A1 (en) 2003-11-13
AU2003227896B2 (en) 2008-08-14
US20050238726A1 (en) 2005-10-27
CA2483097C (en) 2011-07-12
JP2005530750A (ja) 2005-10-13
MXPA04010855A (es) 2005-02-14
US7442383B2 (en) 2008-10-28
AU2003227896A1 (en) 2003-11-17
CA2483097A1 (en) 2003-11-13
JP4939751B2 (ja) 2012-05-30
DE60327068D1 (de) 2009-05-20
ES2323582T5 (es) 2012-08-22
EP1499329B1 (en) 2009-04-08
ATE427750T1 (de) 2009-04-15
ES2323582T3 (es) 2009-07-21

Similar Documents

Publication Publication Date Title
NO20054371L (no) Somatostatin-dopamin kimaere analoger
MEP42808A (en) Use of flibanserin in the treatment of sexual disorders
HRP20050318A2 (en) Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes
NO20062104L (no) Kombinasjonsterapi for HCV-infeksjon
NO20056236L (no) Behandling med anti-VEGF-antistoffer
ECSP056210A (es) Preparación y uso de derivados de alquilarilo para el tratamiento de la obesidad
TW200616632A (en) Compounds modulating c-kit activity and uses therefor
NO20054223L (no) Antistoffmolekyler som har spesifisitet for human IL-1beta
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
BRPI0513367A (pt) arilidenos para o tratamento de doenças mediadas pelo receptor alfa relacionado a estrogênio
BR0309624A (pt) Uso de xenÈnio para o controle de deficiências neurológicas associadas com desvio cardiopulmonar
BRPI0607605A2 (pt) moléculas imunogênicas
ATE448232T1 (de) Substituierte heterozyklen
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
BRPI0519429A2 (pt) composiÇço adequada para melhorar funÇço renal em um animal, mÉtodo para melhorar a funÇço renal em um animal, kit adequado para administrar composiÇÕes para melhorar a funÇço renal a um animal, meio para comunicar informaÇço, e, uso de uma composiÇço
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
MXPA05008438A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6.
EA200400399A1 (ru) Способы лечения легочных заболеваний
ATE512968T1 (de) 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6- carboxamid und 2,3,4,5-tetrahydropyrrolo(1,2-a)- diazepin-7-carboxamid- derivate, ihre herstellung und therapeutische verwendung
DE60221352D1 (de) Zusammensetzung und kit zur verwendung in der tumorbehandlung
BRPI0513825A (pt) combinações de epotilona
TW200628488A (en) Deglycosylated and desialidated long pentraxin PTX3
EP1511713B8 (en) Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments
BRPI0406985A (pt) Terapia de combinação de hcv

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25G Requested change of headquarter approved

Owner name: PROTEXEON LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: IMPERIAL INNOVATIONS LIMITED (GB)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.